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Purpose/Objective: Despite significant research input aiming 
to improve therapy regimens, rectal cancer remains as one of 
the cancers with significant morbidity rates. Radiotherapy 
has been shown to lower 10-year local recurrence by 
approximately 50%. A substantial number of rectal tumours 
fail to respond to radiotherapy which not only presents a 
barrier for effective cancer treatment bu also means that 
those patients with therapy resistant tumours endure the 
harmful side effects of radiotherapy for no therapeutic gain. 
Therefore, it is important to identify biomarkers capable of 
predicting a tumour's response to radiotherapy prior to 
treatment which can improve therapy outcomes. The aim of 
this study is to identify putative protein biomarkers of 
radiotherapy resistance using rectal cancer tissue biopsy 
samples by employing comparative proteomic tools. Ultimate 
aim is to translate these biomarkers into an assay panel for 
routine cancer screening aiding the personalisation of cancer 
treatment. 
Materials and Methods: Following ethical approval (Sheffield 
REC ref 10/H1308/37), two pairs of pre-treatment rectal 
cancer biopsy samples (radioresistant versus radiosensitive) 
were investigated using antibody microarray to identify 
differentially expressed proteins (DEPs) involved in mediating 
radiotherapy resistance. Data obtained from the experiments 
were subjected to data mining using Ingenuity Pathway 
Analysis (IPA) which mapped these DEPs onto their most 
relevant canonical signalling pathways. 
Results: The antibody microarray analysis of the clinical 
samples revealed 25 DEPs and 46 DEPs from the first and the 
second experiment, respectively. The IPA analysis of these 
combined generated 253 canonical pathways. Amongst these, 
the most interesting pathways included p53 signalling (12 
DEPs mapped), death receptor signalling (7 DEPs mapped), 
apoptosis signalling (5 DEPs mapped) and EGF signalling (4 
DEPs mapped). Radiotherapy is known to initiate cellular 
apoptosis via the intrinsic (mitochondrial) apoptotic pathway. 
However, the identification of some regulatory proteins 
involved in the extrinsic pathway (death receptor) apoptotic 
pathway (Figure 1) has revealed a potential link between 
radiotherapy and this pathway. 
 
 
Figure 1: Death Receptor Signalling 
 
A total of 7 DEPs were mapped onto the Death Receptor 
Signalling pathway, namely CRADD, TNFRSF25, MAPK8, 
TNFSF10, NFKB1, TNFRSF10A and TNF. 
Conclusions: Antibody microarray analysis of rectal cancer 
biopsy samples has enabled the identification of a number of 
DEPs which may be involved in mediating response to 
radiotherapy. However, further confirmation with western 
blotting and validation with immunohistochemistry are 
required before such biomarkers can be introduced into 
routine clinical management of cancer patients.  
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Purpose/Objective: The risk of local recurrence, metastases 
and overall survival of locally advanced rectal cancer after 
preoperative chemoradiation and curative surgery can be 
estimated by prediction models and visualized using 
nomograms, which have been trained and validated in 
European clinical trial populations. This study aims to 
validate these prediction models in a routine clinical Chinese 
cohort. 
Materials and Methods: From 2006 to 2012, clinical data of 
277 consecutive locally advanced rectal adenocarcinoma 
patients treated with preoperative chemoradiation and 
curative surgery from a single Chinese Cancer Center, were 
retrospectively collected and used for external validation. 
Concordance index (C-index) and calibration curves were 
used to assess the performance of the previously developed 
